Supplements Europe

Long before probiotics became one of the fastestgrowing categories in health and wellness, the team behind Lab4 was engaged in a scientific pursuit that would ultimately define the company's future. During the 1990s, researchers set out to identify which probiotic strains could deliver the greatest benefit to human health.

As Dr. Nigel Plummer, the CEO and founder of Lab4 recalls, “We screened around 100 strains and only four strains came out at that time as being the most beneficial strains, looking at things like promotion of intestinal health and immune health.”

Those findings laid the foundation for the Lab4 consortium. The original consortium combined two strains of Lactobacillus acidophilus CUL21 and CUL60, one strain of Bifidobacterium animalis subsp. lactis CUL34, and one strain of Bifidobacterium bifidum CUL20. The same four-strain formulation remains central to the company's work and has evolved into a probiotic formulation supported by clinical investigation and a growing body of evidence across multiple areas of health.

The long-term approach has resulted in more than 36 double-blind, placebo-controlled clinical trials and over 70 scientific publications investigating Lab4 family probiotics in multiple health applications. Results demonstrated benefits across digestive health, including relief from constipation, diarrhoea, and symptoms associated with irritable bowel syndrome.

The future of liquid nutraceuticals comes to life at Valentis.

For more than a century, Valentis has elevated the standard of liquid supplements through strong absorption science, a deep respect for nature and a belief that natural ingredients can help people become stronger, recover faster and live better.

Over time, this legacy has shaped Valentis into one of the largest food supplement manufacturers in the Baltic States and a full-scale production partner with in-house laboratory testing, primary and secondary packaging and a strong R&D engine.

“Our objective is to create healthy moments in people’s lives through the products we create,” says Linas Kamarauskas, Business Development Manager.

Science Behind the Difference

Valentis pursues its goal by bringing together nature and science.

Liquid formats often rely on clean raw materials, balanced dosing, multi-year stability and great taste. The pursuit for excellence in this led Valentis to one of its breakthroughs, the patented MiosolTM microencapsulation technology.

Using phospholipid-based microcapsules that mimic natural cell structures, Miosol^TM:

• shields active ingredients for maximum stability

• protects nutrients from stomach acidity

• enhances absorption rates by up to six times

• improves the stability of light- and oxygen-sensitive compounds

• delivers fat- and water-soluble substances in fully dissolved, highly bioavailable form

Cell Wellbeing is recognised globally for its pioneering digital epigenetic mapping technology. It helps practitioners to consider how environmental stressors, electromagnetic fields, dietary influences and lifestyle choices may be impacting the individual wellness.

Through a simple, non-invasive hair mapping process, wellness and sports fitness specialists receive personalised nutritional and wellbeing insights. These empower practitioners to design their own tailored recommendations, to support their clients in achieving a balanced physical, mental, and emotional wellbeing.

“We believe wellness is shaped by lifestyle, the environment and nutrition.”

Many daily factors can influence wellness and performance, such as environmental stressors and poor dietary habits—yet often they are overlooked. These subtle yet persistent challenges can impact the body’s balance and overall vitality. By highlighting them in a clear, legible report, Cell Wellbeing provides practitioners with additional insight into potential underlying stressors.

The process begins with the collection of four hair strands. This includes the hair bulbs, where additional valuable information is stored. This data is captured by the S Drive, Cell Wellbeing’s proprietary device, and transmitted securely via the web to the company’s technology hub in Germany. There, advanced systems interpret over 800 epigenetic indicators related to nutrition, environment and lifestyle.

The gathered information is returned within minutes to the practitioner’s S Drive, presenting key information in an easy-to-understand format. The returned data highlights personalised factors, such as vitamins, minerals, amino acids and environmental influences. The data is prioritized by relevance and impact to the person’s health.

Privacy and data protection are integral part and key factors in this process. Only anonymised codes are being transmitted, never a full name.

Koncare Biotech, under the leadership of CEO and founder Concha Pérez, has firmly established itself as a pioneering force in the treatment of digestive disorders. Founded in 2019 with the goal of leading the care and improvement of patients’ quality of life, it is at the forefront of the development of natural products endorsed by strict quality standards.

The forward-thinking company is making significant strides in the rapidly evolving nutraceutical industry, leveraging clinical research, a deep understanding of gut health, and cutting-edge science to provide effective solutions. Specializing in digestive pathologies, Koncare’s holistic and integrative approach addresses the root causes of common ailments such as irritable bowel syndrome (IBS), intestinal dysbiosis, and metabolic-associated fatty liver disease (MAFLD), setting it apart from other players in the market.

What makes Koncare truly unique, according to Mrs. Pérez is the company’s ability to blend applied clinical research with an integrative vision of health. It stands out by developing products with a solid scientific foundation that are also highly personalized for each digestive condition. This evidence-based, individualized approach enables Koncare to tackle complex, multifactorial digestive issues in a way that aligns with the latest scientific trends, anticipating developments in neurogastroenterology and gut microbiota.

“We incorporated principles of neurogastroenterology and gut microbiota long before they became mainstream,” Concha Pérez notes, underscoring the company’s commitment to staying ahead of the curve.

Its ability to foresee industry shifts is one reason Koncare recently expanded internationally, securing a distribution agreement in the UAE with Dr. Safwan Nached, CEO of Pharmapal—further solidifying its global presence.

Koncare’s product portfolio reflects its philosophy of clinical innovation. Among the standout offerings is Disibex Forte, a specialized formulation designed to treat functional dyspepsia. This product goes beyond symptomatic relief by targeting the underlying pathophysiological mechanisms.

Disibex Forte’s unique combination of probiotic strains, plant extracts, digestive enzymes, and immune modulators makes it one of a kind in its category. It also plays a crucial role as an adjuvant in Helicobacter pylori eradication therapy and in preventing and treating travelers’ diarrhea.

Another key product, Metabok, offers an integrative solution for MAFLD, a condition often associated with metabolic and cardiovascular issues. Metabok’s formulation is designed to modulate gut microbiota, reduce hepatic lipid accumulation, and improve liver and cardiovascular health. It incorporates probiotics, vitamin E, phytolized silymarin, and resveratrol. These innovations reflect Koncare’s commitment to efficacy, safety, and pathophysiology-based therapeutic solutions.

The United Kingdom is strengthening its position within the global probiotics sector through research-backed consortia that combine academic expertise, clinical investigation, and commercial planning. As healthcare systems increasingly prioritise preventive care and microbiome science, collaborative probiotic initiatives are attracting attention from investors, manufacturers, and policy advisers.

These consortia are creating structured pathways for translating laboratory findings into scalable healthcare and nutrition applications. Their influence extends beyond product development because they also support regulatory alignment, supply chain modernisation, and international research partnerships. This coordinated approach is helping the United Kingdom establish a commercially sustainable environment for microbiome innovation while encouraging long-term growth across healthcare-related industries and scientific research markets.

Building Commercial Value through Collaboration

Research consortia within the United Kingdom are quietly encouraging cooperation between universities, biotechnology specialists, ingredient suppliers, and healthcare institutions. This kind of setup helps participants exchange clinical data, research infrastructure, and technical know-how while also cutting back on duplicated investment. Businesses entering the probiotics market are starting to see that scientific credibility has become kind of a must if they want real consumer trust and regulatory acceptance.

So studies led by consortia are giving organisations a way to tighten their evidence-based positioning inside really crowded health and nutrition spaces. Investors look at this and respond favourably because products that are scientifically validated often show steadier market behaviour, more pricing freedom, and longer-term commercial performance that holds up across both domestic and international healthcare arenas.

Targeted probiotic strains are also changing where investment attention goes. Researchers are turning their focus toward microbiome applications tied to digestive health, metabolic steadiness, and healthy ageing, mostly because those areas match rising healthcare spending and the shifting demographic picture.

"Research consortia within the United Kingdom are quietly encouraging cooperation between universities, biotechnology specialists, ingredient suppliers, and healthcare institutions."

Commercial stakeholders are asking how research results can feed differentiated product catalogues—ones that can serve medical expectations and everyday consumer wellness needs. In practice, this approach can help manufacturers step away from general formulas, toward more specific, clinically supported options. Meanwhile, healthcare providers are showing more curiosity about threading microbiome-related products into wider wellness plans, those that back preventive care goals and support longer-term patient management plans.

Regulatory Standards Encouraging Market Expansion

The regulatory situation around probiotics is still pretty complicated, since health-related claims demand strong scientific validation. In the United Kingdom, partnerships between research groups are helping businesses handle these requirements by creating structured clinical evidence and strengthening dialogue between research institutions and policymakers.

Companies that join collaborative research initiatives may also get earlier insight into changing standards so that they can tweak development plans more smoothly. That readiness can limit operational ambiguity, and it supports stronger market positioning across healthcare plus nutritional sectors. As regulatory expectations keep moving internationally, organisations that already have validation through research are expected to gain advantages in market entry, product approval paths, and longer-term commercial credibility with distributors and healthcare professionals.

Supply chain planning is getting more important too, as probiotic production expands into more international markets. Temperature-controlled logistics, ingredient traceability, and standardised manufacturing practices are now pretty central for organisations trying to protect both quality and regulatory compliance. Research consortia are contributing by setting technical frameworks that push consistency across production and distribution systems.

This coordination can boost reliability in the market while lowering exposure to product variation and extra complications from international trade rules. Businesses that can keep production standards stable are more likely to pull in institutional partnerships and investment backing, especially in areas where healthcare regulators strongly value transparency and manufacturing accountability within nutrition-related industries.

Future Investment Opportunities across Healthcare

The long-term outlook for the United Kingdom's research-backed probiotic consortia seems closely tied to preventive healthcare approaches and personalised nutrition models. healthcare systems are increasingly searching for cost-effective methods that support population wellness, while reducing stress on clinical services. Probiotic research fits into that narrative because microbiome science can help broaden health management frameworks and nutritional planning initiatives.

Private investment is expected to stay active as institutional investors chase exposure to healthcare innovation, but only when there are measurable scientific outcomes to point to. Research consortia feel like an appealing structure because they limit uncertainty through shared expertise, joint validation processes, and coordinated commercialisation strategies, which adds operational durability in competitive healthcare and biotechnology markets.

As the microbiome knowledge base keeps shifting and getting deeper, United Kingdom probiotic consortia are likely to influence international healthcare and nutrition markets through research quality, operational coordination, and commercial adaptability. Their collaborative approach basically shows how scientific credibility and business planning can run together to back sustainable growth, encourage responsible investment, and open doors in the wider global healthcare economy.

Ongoing alignment among academic institutions, manufacturers, healthcare providers, and policymakers may strengthen the sector further by improving innovation efficiency and increasing broader consumer acceptance. This setting puts the United Kingdom in a prominent role as a future participant in evidence-based probiotic solutions, and also in commercially sustainable healthcare research initiatives worldwide.

The post-genomic era has ushered in a new understanding of biology, shifting focus from the static blueprint of the genome to the responsive layer of the epigenome. This regulatory layer, comprising mechanisms like DNA methylation, histone modifications, and non-coding RNAs, acts as the software that runs the genetic hardware.

For decades, exploring this layer was the exclusive domain of highly specialised academic research labs. Today, the European landscape is witnessing a profound commercial inflexion point. The convergence of plummeting next-generation sequencing costs, an explosion in computational power, and the maturation of AI has given birth to a new industry: digital epigenetic mapping as a commercial service. This article analyses the market trends, service provider archetypes, and investment currents driving this rapid transition from pure research to sustainable revenue across Europe.

Key European Market Drivers

The pivot to commercial epigenetic services is driven by powerful market demands rather than speculation, as these models uniquely translate complex, multi-omic datasets into actionable biological insights. The healthcare industry’s transition toward precision medicine is a central force, moving away from one-size-fits-all treatments toward individualised care. Epigenetic markers— tissue-specific and reflective of environmental factors—are becoming indispensable in patient stratification, drug target discovery, and companion diagnostic development. Pharmaceutical firms increasingly rely on specialised providers to leverage these insights for clinical and therapeutic innovation.

Simultaneously, a growing consumer and wellness market is propelling demand beyond traditional healthcare. The rise of preventative health and longevity services, centred around “epigenetic clocks” that assess biological age, is gaining traction among European consumers, corporate wellness programs, and private clinics seeking measurable indicators of healthspan improvement. This expansion is enabled by rapid technological maturation: plummeting costs of genome-scale sequencing, scalable cloud-based data infrastructure, and advanced AI algorithms capable of extracting predictive biological patterns from massive datasets. Together, these forces have transformed epigenetic analysis from a research tool into a commercially viable cornerstone of personalised and preventative healthcare.

Structuring the New Service Ecosystem

Across Europe, a new and diverse ecosystem of service providers is emerging in response to key industry drivers, particularly around established biotechnology and academic hubs. These organisations are innovating beyond traditional models of selling kits or instruments, shifting instead toward providing access to data, insights, and integrated digital platforms. This transformation is fostering several dominant archetypes that define the evolving landscape of bioinformatics and genomics services.

The “Pure-Play” Analytics Platform consists of bio-IT or software-as-a-service (SaaS) providers that specialise in cloud-based bioinformatics solutions without operating their own wet labs. Clients—ranging from academic researchers to pharmaceutical R&D teams—upload raw sequencing data, which is then processed using proprietary algorithms and reference databases to generate comprehensive, interpretable reports. This model’s scalability and reliance on advanced analytics make it ideal for organisations that have sequencing capabilities but lack the computational infrastructure or expertise.

The “Sample-to-Insight” Integrated Providers and Niche Application Specialists offer more targeted value propositions. Integrated providers handle the entire workflow—from biological sample collection to sequencing and analysis—delivering turnkey solutions favoured by pharmaceutical and corporate wellness clients. In contrast, niche specialists focus intensely on specific applications, such as oncology diagnostics, neurodegenerative biomarkers, or consumer longevity insights. Their specialisation enables the development of curated datasets and refined algorithms, establishing a strong competitive edge within their chosen domains.

Mapping the Investment Currents in Europe

Investment flows are unequivocally validating the viability of this new sector. Venture capital, corporate partners, and public bodies across Europe are actively deploying capital, recognising the transformative potential of applied epigenetics.

In a new "Bio-IT" asset class, investors are particularly drawn to the business models. Unlike traditional biotech, which often faces binary outcomes and decade-long R&D timelines, digital epigenetic services are frequently structured as "bio-IT" or SaaS companies. European venture capital firms, including both specialist health-tech funds and generalist tech investors, have been actively participating in seed and Series A funding rounds, with financing frequently reaching into the tens of millions of euros.

Beyond private VCs, capital is flowing from the corporate venture capital (CVC) arms of major pharmaceutical, diagnostic, and chemical companies, which are making strategic investments. For them, this is a way to gain early access to cutting-edge technology, scout for potential acquisition targets, and establish partnerships that feed their internal R&D pipelines.

The robust European public funding landscape remains a critical catalyst. Grants from the European Research Council, Horizon Europe, and various national innovation agencies (such as those in Germany, France, and the UK) are crucial for de-risking the foundational science. This public support often acts as a bridge, allowing university spin-offs and early-stage startups to validate their technology to the point where they can attract significant private investment. The investment thesis itself is clear: the race is on to build the most extensive, most deeply annotated, multi-omic datasets. The ultimate value lies not just in a single test, but in the data-driven ecosystem and the predictive engine it powers.

The European digital epigenetic mapping sector has successfully navigated the challenging transition from a purely academic pursuit to a commercial industry. Driven by the specific demands of precision medicine and preventative health, a new ecosystem of service providers is taking shape, offering scalable solutions from pure analytics platforms to full-service integrated labs. Validated by strong and diverse investment streams, this industry is no longer a future promise. It is a present-day reality, positioning epigenetic insights as a standard, indispensable component of biomedical research and healthcare delivery.

In Europe, the nutraceutical industry is transitioning from a generalized approach to a personalized, biomarker-driven model, particularly for managing digestive disorders. The market for nutraceuticals addressing digestive health is robust and expanding, as consumers increasingly seek preventative and targeted solutions. This is where the application of biomarkers—measurable indicators of a biological state—becomes critical.

The Role of Biomarkers in Personalized Digestive Health

The human digestive system is a highly complex and dynamic ecosystem, with the definition of “healthy” varying significantly from one individual to another. Conventional nutraceutical recommendations for digestive issues often rely on generalized categories such as probiotics or fiber supplements; however, these broad approaches may not be universally suitable or practical. The use of biomarkers offers a more precise and individualized assessment, providing insights into specific aspects of digestive health by uncovering the underlying mechanisms of a given pathology rather than relying solely on general symptoms.

Microbiome profiling plays a pivotal role in this personalized approach. Through metagenomic sequencing—which examines the genetic material of microorganisms within a sample—it is possible to obtain a detailed picture of the gut microbiota’s composition and function. Such analysis can identify imbalances, including a deficiency in beneficial bacteria, an overgrowth of harmful species, or a state of dysbiosis. Based on these findings, targeted nutraceutical interventions, such as specific prebiotics or probiotics, can be recommended to restore microbial balance.

Similarly, inflammatory markers provide critical insights for conditions characterized by chronic inflammation, such as inflammatory bowel disease (IBD). Biomarkers like calprotectin and C-reactive protein (CRP) can indicate both the presence and severity of gut inflammation. Monitoring these markers enables healthcare providers to assess the effectiveness of nutraceutical interventions, such as omega-3 fatty acids or curcumin, in reducing inflammation and enhancing patient outcomes.

Another powerful tool is metabolomic analysis, which studies small molecules (metabolites) produced by both the body and the gut microbiome. Metabolomic signatures can reveal disruptions in metabolic processes and their relationship to diet and disease. For instance, assessing short-chain fatty acids (SCFAs)—produced when gut bacteria ferment dietary fiber—offers valuable insights into microbiome function. A reduced level of butyrate, a critical SCFA, may indicate the need for nutraceutical strategies aimed at promoting the growth of butyrate-producing bacteria.

Key Nutraceuticals and Their Targeted Application

The integration of biomarkers into nutraceutical interventions enables the precise and targeted application of a diverse range of compounds, enhancing efficacy and providing a robust scientific foundation for their role in digestive health. Among the most widely recognized categories are probiotics and prebiotics—probiotics being live microorganisms that confer health benefits to the host, and prebiotics being non-digestible compounds that promote the growth of these beneficial bacteria. Biomarkers are crucial in selecting the appropriate probiotic strain and prebiotic type. For instance, a microbiome analysis indicating low levels of Bifidobacterium may warrant supplementation with that specific strain, paired with a prebiotic such as galactooligosaccharides (GOS) to encourage its proliferation. Similarly, polyphenols and antioxidants, which are abundantly found in fruits, vegetables, and spices, such as curcumin and quercetin, exhibit strong anti-inflammatory and antioxidant properties. Elevated inflammatory biomarkers can indicate the need for these nutraceuticals to modulate inflammatory responses, while metabolomic analysis of oxidative stress markers can guide the selection of targeted antioxidant-rich compounds. Additionally, in cases of malabsorption or impaired nutrient breakdown, digestive enzyme supplementation may be appropriate. Biomarkers of nutrient deficiency, such as low albumin, can signal the need for protein complexes or amino acid supplements to optimize protein status and overall nutritional health.

The European Market Landscape

The European nutraceutical market, particularly within the digestive health sector, is experiencing substantial expansion. This growth is driven by an aging demographic, a rising incidence of gastrointestinal disorders, and increased public awareness of the connection between gut health and overall well-being. A notable trend is the growing demand for personalized nutrition, as consumers are increasingly willing to invest in tailored and customized solutions. The integration of biomarker analysis is perceived as a premium feature that validates product efficacy and provides a scientific underpinning for its utilization. This has instigated a shift in product development, emphasizing the creation of evidence-based formulations and technologies that support a biomarker-driven methodology. The market is transitioning towards products that transcend general supplementation, being specifically engineered to address identified metabolic and microbial imbalances through diagnostic testing. This evolution is fundamentally reshaping the industry, fostering a more scientific and individualized approach to health and wellness.

The convergence of advanced biomarker technology and the European nutraceutical market marks a pivotal juncture in the advancement of digestive health. This emerging paradigm transcends generalized recommendations, embracing instead a sophisticated, data-driven methodology. By harnessing insights derived from microbiome profiling, inflammatory markers, and metabolomic analysis, healthcare professionals and consumers are now empowered to render informed, targeted decisions concerning nutraceutical utilization. This bespoke approach not only enhances the potential efficacy of such interventions but also fosters a deeper understanding of individual health at a molecular level. As this trend continues to mature, it is poised to redefine the landscape of preventive and therapeutic strategies for digestive pathologies, offering a more precise, scientific, and ultimately, more efficacious pathway toward optimal gut health for a diverse and discerning European populace. This transformation underscores a broader movement toward a future in which health and nutrition are inextricably linked to individual biological data, heralding a new era of truly personalized wellness.

Advanced Therapies, including cell therapies, gene therapies and gene editing products, are one of the leading current developments in the biopharmaceutical world. Buoyed and driven by the promise of creating a life changing treatment for rare diseases and in some cases, offering the hope of a potential cure for patients, this field is revolutionising the way we approach everything from clinical trial design, to regulatory expectations and re-imbursement policies.

Yet gene therapies themselves are not new. The first gene therapy human dose administration was just over thirty years ago (1990), however, gene therapy faced several setbacks and challenges, but continued investment in technology and regulatory science in this field has supported the advancement.  Recent data shows that the number of clinical trials underway in the US with gene therapies rose during the period 2020 to 2021 from 410 to 522 trials, with approaching 7 percent of those trials in Phase 3 and pre-registration stages. In the same report, data showed that 89 percent of gene therapies utilise viral vectors for delivery, with Adeno-Associated Virus (AAV) being the most prevalent gene delivery vehicle.

Two recent approvals of AAV gene therapy drugs are major contributors to the resurgence in investment in gene therapies as medical treatments and potential cures: (1) approval of Luxturna in 2017 by FDA and 2018 by EMA, which is a single injection in each eye of an AAV carrying a functional copy of the RPE65 gene into the retinal cells for the treatment of an inherited form of vision loss and (2) approval of Zolgensma in 2019 by FDA and 2020 by EMA for a one-time intravenous injection of AAV9 which carries a functional copy of SMN1 for treatment of spinal muscular atrophy.

Having originally focused on rare diseases with small patient populations, such as retinal dystrophy (anticipated 1000-2000 patients in US³) and spinal muscular atrophy (10,000 to 25,000 patients in US), drug developers are now turning their attention to treating prevalent diseases. The Alliance for Regenerative Medicine (ARM) presented data that shows that almost 60 percent of the 2,400 Regenerative Medicine clinical trials at the end of 2021 targeted prevalent diseases, such as diabetes and Parkinson’s⁵.

With rare diseases and the very small number of patients, many of the indications require relatively low doses,for example Luxturna (1.5 x 10¹¹ vector genomes in 0.3ml). This translates into a low drug substance and drug product demand and therefore drug substance manufacturing batch size.  In early clinical trials there are tens of patients, and the stability demand can outweigh the demand of drug product for the patients in the trial.  As a result, many drug developers in the field are continuing to use the traditional methods of manufacture, for example adherent cell systems in cell stacks with animal serum and purification through ultracentrifugation. These processes are manual and rely on scaling-out rather than scaling-up. As the demand for drug substance increases, these processes become labour intensive, logistically challenging and open to more opportunities for issues with contamination and batch-to-batch consistency. 

Whilst the traditional processes have enabled scientists to provide sufficient quantities of drug product for early clinical trials and proof-of-concept, developers are increasingly looking to switch to alternative scalable manufacturing processesfor their late phase development and commercial production. At later stages of development, drug product needs escalate as material is required for clinical studies, analytical method validation, product stability, and process characterisation using orthogonal analytical technologies in readiness for registration and commercial supply.

Outsourcing activities in the pharmaceutical industry are common. It helps save on costs like resources, infrastructure, and overhead. When it comes to quality, outsourcing offers similar benefits. Small to mid-sized organizations can get expert guidance to make sure their quality management system (QMS) aligns with their current drug development phase. This helps them improve their QMS as they grow. Larger firms can use outsourcing to bridge any resource gaps or for specialized, short-term quality projects.

However, there are risks in outsourcing quality support. These include ensuring timely and high-quality deliverables, compliance with regulations, maintaining confidentiality, and lack of flexibility. To mitigate these risks, it’s crucial to set clear expectations with quality consultants before the project starts. It’s vital to note that even when outsourcing, the license holder remains responsible for their QMS. They will be accountable to any regulatory body, regardless of who manages the quality function. Therefore, organizations should thoroughly vet consultants to ensure they have the needed qualifications and training.

Here are some frequently outsourced quality functions in the pharmaceutical sector:

1. eQMS Administration: Outsourcing can benefit any sized organization that needs expertise in setting up and running the system. Smaller firms often lack in[1]house validation or quality experts for an eQMS setup. Consultants can handle most tasks remotely, from setting up the system to training users.

[QUOTE1_Replace]

2. Document Management: Consultants can oversee this using your eQMS or other platforms like SharePoint®. It’s essential to ensure that electronic signature tools comply with regulations like 21 CFR Part 11.

3. Training: This is crucial to meet pharmaceutical industry regulations. Consultants can help set up training programs, ensuring employees understand regulations, procedures, and processes. They can also offer specialized regulatory training.

4. Batch Record Review: Essential for ensuring drug quality and safety, consultants offer an unbiased view, especially if in-house staff are deeply involved in processes.

5. Validation: Often outsourced, even by larger companies. While some validation activities might require on-site presence, tasks like computer system validation (CSV) can be remote.

6. Auditing: Remote auditing has grown popular recently. While cost[1]effective, the risks and benefits of remote auditing, especially for manufacturing sites and initial vendor qualifications, need consideration.

7. Remediation: External experts can offer fresh perspectives and process improvements.

Outsourcing quality-related functions goes beyond merely signing a contract. While many of these functions can be effectively outsourced, the ultimate responsibility for product quality and regulatory compliance always rests with the organization, whether it’s the sponsor or market authorization holder. This makes it imperative to select highly experienced and qualified consultants. Equally vital is ensuring these consultants undergo company-specific training, with proper documentation and maintenance of this training. This approach not only safeguards regulatory adherence but also leverages the efficiencies and expertise that outsourcing offers, reinforcing it as a sound and effective strategy.

In your experience as a managing director at Eurofins, what would you say are some of the recent changes you witnessed regarding the implementation and use of technology?

The core of my work is linked to the world of cell and gene therapies. It is that part of life sciences where innovation is important and is something that the industry is proactively looking for. Cell and gene therapies are innovative medicine, as they can provide life-changing solutions and ultimately be a physician's weapon. However, there is currently no clear model for those.

We have autologous and allogeneic cells, fresh and frozen cells. These are pieces of the puzzle that can make these products simpler from a manufacturing perspective or, more importantly, more sustainable from an industry perspective. Sustainability is the key element for manufacturing cell and gene therapies.

How important is collaboration when it comes to developing and researching new medications?

Historically, collaboration is how the front runners in cell and gene therapy were developed. Identifying the right strategy or the right target for cell and gene therapy and medicine was a major priority. It is vital that young startups, biotech organizations, and other companies with fresh portfolios can leverage collaboration.

In the early days, we witnessed something that reflected true collaboration. In today's world, it is about recognizing the value that each team member brings. That is also why it is so common to see big consortiums at the European level trying to develop new medicine.

How has technology helped you accelerate your projects and make your cell and gene therapies safer, scalable, affordable, and more efficient?

For many years, the big question was about how we could manufacture cell and gene therapies. Our new focus is on making them sustainable. The important aspect of being sustainable is analyzing the impact of innovation, new tools, and collaboration on cutting costs for manufacturing, goods, and logistics. Engaging with regulatory bodies from a pricing and reimbursement perspective also plays a key role in sustainability. We are at a point where making products more sustainable begins with the manufacturing process.

Additionally, we should not solely look at prices from a material-purchasing perspective but the cost to achieve good quality as well. How risky would it be to produce products using tools that, for instance, are not completely valid? If a batch is lost, that is an enormous financial loss. Instead, using advanced and verified technology can reduce the risk created when achieving quality.

How important is patient data for achieving and maintaining sustainability?

We have often seen a return to a "one product, one patient" mindset, especially for cell and gene therapies, but not all patients respond in the same way. 

How do you foresee ongoing changes in services for oncology shaping the landscape of challenges you face in satisfying your business requirements?

The ongoing changes and innovations in oncology are a challenge to any organisation. The London Clinic is continually adapting its approach to ensure we deliver exceptional patient care with options to meet their individual needs. This requires ongoing investment and agile working. We at the London Clinic are evolving our strategies to ensure we meet future oncology challenges. Our focus includes:

Technological Advancements: As new technologies emerge, such as precision medicine, gene therapy and immunotherapy, we will adapt our services to be at the forefront of the trial and align our key areas of clinical strategy to these advancements

Patient-Centric Care: We have always been focused on delivering patient-centric care. We prioritise the development of products or services that cater to the individual needs and preferences of cancer patients, and this could be provided by the London Clinic or in partnership.

Partnerships: The interdisciplinary nature of oncology care requires a comprehensive service offering, and we foresee forging partnerships with other healthcare providers or organisations to deliver comprehensive solutions that provide personalised patient care.

Cost Pressures: Rising healthcare costs and reimbursement challenges will impact the viability of delivering oncology care; we continue to evolve our care and ensure that we offer value-based care

Compliance: Changes in regulations surrounding oncology treatments will need us to be flexible and agile to ensure compliance and adherence to standards.

Data Management: With the increasing emphasis on data-driven decision-making in healthcare, we, like other organisations, face challenges related to the collection, storage, and analysis of large volumes of patient data.

Are there specific challenges within oncology that you believe are not adequately met by the current range of services?

The London Clinic has a wide range of services, and we are fortunate to be able to provide a comprehensive service offering to our patients.Addressing these challenges requires a multifaceted approach that, for us, will involve collaboration with healthcare providers, investment 

Our current service does have some general challenges that are commonly faced by other organisations and include:

Innovative Treatments: The field of oncology is rapidly evolving, with new treatments and technologies constantly being developed. Ensuring that patients have access to the latest advancements in cancer care, such as targeted therapies, immunotherapy, and precision medicine, is a challenge

Holistic Care and Patient Experience: Cancer diagnosis and treatment can be emotionally and physically taxing for patients. Providing comprehensive support services, such as psychological counselling, palliative care, and survivorship programs, is important for addressing the holistic needs of patients and their families.